PharmaCielo Ltd. (TSXV:PCLO)
Canada · Delayed Price · Currency is CAD 0.0600
0.00 (0.00%)
Aug 28, 2026, 12:01 PM EST
PharmaCielo Income Statement
Financials in millions CAD. Fiscal year is April - March.
Millions CAD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| 3.6 | 2.54 | 3.17 | 3.48 | 1.54 | 5.31 | |
Revenue Growth | 32.87% | -20.08% | -8.81% | 125.70% | -70.96% | 172.93% |
Cost of Revenue | 2.3 | 1.81 | 2.8 | 2.75 | 2.91 | 4.27 |
Gross Profit | 1.3 | 0.73 | 0.37 | 0.73 | -1.37 | 1.04 |
Selling, General & Admin | 4.3 | 3.98 | 5.11 | 5.42 | 8.31 | 11.66 |
Other Operating Expenses | -0.03 | -0.15 | -0.21 | -0.24 | -0.09 | -0.15 |
Operating Expenses | 4.43 | 3.91 | 5.09 | 5.4 | 8.58 | 11.97 |
Operating Income | -3.13 | -3.19 | -4.72 | -4.67 | -9.95 | -10.93 |
Interest Expense | -2.41 | -2.39 | -3.19 | -2.26 | -2.69 | -1.54 |
Interest & Investment Income | - | - | 0 | 0 | 0 | 0 |
Earnings From Equity Investments | - | - | - | - | - | -1 |
Currency Exchange Gain (Loss) | -0.34 | -0.34 | -0.08 | -0.1 | 0.09 | -0.12 |
Other Non Operating Income (Expenses) | -0.44 | -0.21 | -0.3 | -1.35 | 0.07 | 0.42 |
EBT Excluding Unusual Items | -6.31 | -6.13 | -8.29 | -8.37 | -12.48 | -13.15 |
Gain (Loss) on Sale of Investments | - | - | -0.19 | - | 0.03 | -0.14 |
Gain (Loss) on Sale of Assets | 2.28 | 2.24 | - | - | - | 0.04 |
Asset Writedown | - | - | -0.66 | -0.82 | -4.23 | -1.27 |
Other Unusual Items | 0.31 | 0.31 | 0.04 | 0.05 | 0.39 | - |
Pretax Income | -3.71 | -3.58 | -9.1 | -9.14 | -16.3 | -14.52 |
Net Income | -3.71 | -3.58 | -9.1 | -9.14 | -16.3 | -14.52 |
Net Income to Common | -3.71 | -3.58 | -9.1 | -9.14 | -16.3 | -14.52 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 193 | 188 | 174 | 171 | 160 | 151 |
Shares Outstanding (Diluted) | 193 | 188 | 174 | 171 | 160 | 151 |
Shares Change | 8.00% | 8.09% | 1.96% | 6.83% | 6.03% | 3.67% |
EPS (Basic) | -0.02 | -0.02 | -0.05 | -0.05 | -0.10 | -0.10 |
EPS (Diluted) | -0.02 | -0.02 | -0.05 | -0.05 | -0.10 | -0.10 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -6.96 | -4.61 | -1.69 | -1.97 | -5.17 | -10.4 |
Free Cash Flow Per Share | -0.04 | -0.02 | -0.01 | -0.01 | -0.03 | -0.07 |
Gross Margin | 36.19% | 28.59% | 11.77% | 21.00% | -88.78% | 19.55% |
Operating Margin | -86.73% | -125.75% | -148.74% | -134.06% | -645.41% | -205.85% |
Profit Margin | -103.08% | -141.06% | -286.63% | -262.70% | -1057.09% | -273.45% |
Free Cash Flow Margin | -193.01% | -181.86% | -53.10% | -56.59% | -335.01% | -195.86% |
EBITDA | -1.82 | -1.79 | -3.41 | -4.53 | -8.57 | -10.55 |
EBITDA Margin | -50.59% | -70.38% | -107.34% | -130.12% | - | -198.76% |
D&A For EBITDA | 1.3 | 1.4 | 1.31 | 0.14 | 1.38 | 0.38 |
EBIT | -3.13 | -3.19 | -4.72 | -4.67 | -9.95 | -10.93 |
EBIT Margin | -86.73% | -125.75% | -148.74% | -134.06% | - | -205.85% |
Revenue as Reported | 3.6 | 2.54 | 3.17 | 3.48 | 1.54 | 5.31 |